Mapping the journey of transition: a single-center study of 170 childhood-onset GH deficiency patients

Objective To analyze metabolic parameters, body composition (BC), and bone mineral density (BMD) in childhood-onset GH deficiency (COGHD) patients during the transition period (TP). Design Single- center, retrospective study was performed on 170 consecutive COGHD patients (age 19.2 ± 2.0 years, range 16–25) transferred after growth completion from two pediatric clinics to the adult endocrine unit. Two separate analyses were performed: (i) cross-sectional analysis of hormonal status, metabolic parameters, BC, and BMD at first evaluation after transfer from pediatrics to the adult department; (ii) longitudinal analysis of BC and BMD dynamics after 3 years of GH replacement therapy (rhGH) in TP. Results COGHD was of a congenital cause (CONG) in 50.6% subjects, tumor-related (TUMC) in 23.5%, and idiopathic (IDOP) in 25.9%. TUMC patients had increased insulin and lipids levels (P < 0.01) and lower Z score at L-spine (P < 0.05) compared to CONG and IDOP groups. Patients treated with rhGH in childhood demonstrated lower fat mass and increased BMD compared to the rhGH-untreated group (P < 0.01). Three years of rhGH after growth completion resulted in a significant increase in lean body mass (12.1%) and BMD at L-spine (6.9%), parallel with a decrease in FM (5.2%). Conclusion The effect of rhGH in childhood is invaluable for metabolic status, BC, and BMD in transition to adulthood. Tumor-related COGHD subjects are at higher risk for metabolic abnormalities, alteration of body composition, and decreased BMD, compared to those with COGHD of other causes. Continuation of rhGH in transition is important for improving BC and BMD in patients with persistent COGHD.

[1]  C. Alter,et al.  Adult growth hormone deficiency: Optimizing transition of care from pediatric to adult services. , 2020, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[2]  S. Radovick,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE. , 2019, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[3]  G. Binder,et al.  Changes in body composition in male adolescents with childhood‐onset GH deficiency during transition , 2019, Clinical endocrinology.

[4]  A. Verrotti,et al.  Growth Hormone (GH) Therapy During the Transition Period: Should We Think about Early Retesting in Patients with Idiopathic and Isolated GH Deficiency? , 2019, International journal of environmental research and public health.

[5]  M. G. Shaikh,et al.  Childhood-onset growth hormone deficiency and the transition to adulthood: current perspective , 2018, Therapeutics and clinical risk management.

[6]  Z. Şıklar,et al.  Prospective Follow-up of Children with Idiopathic Growth Hormone Deficiency After Termination of Growth Hormone Treatment: Is There Really Need for Treatment at Transition to Adulthood? , 2018, Journal of clinical research in pediatric endocrinology.

[7]  D. Grujičić,et al.  Clinical case seminar: Familial intracranial germinoma. , 2018, Endokrynologia Polska.

[8]  M. Stojanović,et al.  Etiology of Hypopituitarism in Adult Patients: The Experience of a Single Center Database in the Serbian Population , 2017, International journal of endocrinology.

[9]  S. Ahmed,et al.  Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement , 2016, Endocrine connections.

[10]  G. Leese,et al.  An audit of the management of childhood-onset growth hormone deficiency during young adulthood in Scotland , 2016, International Journal of Pediatric Endocrinology.

[11]  M. Polak,et al.  Monocentric study of 112 consecutive patients with childhood onset GH deficiency around and after transition. , 2013, European journal of endocrinology.

[12]  M. Kołtowska-Häggström,et al.  Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction. , 2013, European journal of endocrinology.

[13]  E. Inzaghi,et al.  The Challenge of Growth Hormone Deficiency Diagnosis and Treatment during the Transition from Puberty into Adulthood , 2013, Front. Endocrinol..

[14]  E. Tsalikian,et al.  United States multicenter study of factors predicting the persistence of GH deficiency during the transition period between childhood and adulthood , 2013, International Journal of Pediatric Endocrinology.

[15]  G. Stalla,et al.  Changes in BMI and management of patients with childhood onset growth hormone deficiency in the transition phase. , 2012, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[16]  S. Greenspan,et al.  A longer interval without GH replacement and female gender are associated with lower bone mineral density in adults with childhood-onset GH deficiency: a KIMS database analysis. , 2012, European journal of endocrinology.

[17]  C. Gordon,et al.  Bone density in post‐pubertal adolescent survivors of childhood brain tumors , 2012, Pediatric blood & cancer.

[18]  M. Kołtowska-Häggström,et al.  GH deficiency during the transition period: clinical characteristics before and after GH replacement therapy in two different subgroups of patients , 2012, Journal of pediatric endocrinology & metabolism : JPEM.

[19]  C. Shin,et al.  Risk factors for osteoporosis in long-term survivors of intracranial germ cell tumors , 2012, Osteoporosis International.

[20]  P. Chanson,et al.  Growth hormone effects on cortical bone dimensions in young adults with childhood-onset growth hormone deficiency , 2011, Osteoporosis International.

[21]  S. Bechtold,et al.  Early changes in body composition after cessation of growth hormone therapy in childhood-onset growth hormone deficiency. , 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[22]  H. Wollmann,et al.  Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency. , 2010, The Journal of clinical endocrinology and metabolism.

[23]  R. Pieters,et al.  Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  P. Chanson,et al.  Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. , 2009, European journal of endocrinology.

[25]  E. Krenning,et al.  Bone Mineral Density and Body Composition in Adolescents with Childhood-Onset Growth Hormone Deficiency , 2009, Hormone Research in Paediatrics.

[26]  M. Kołtowska-Häggström,et al.  Impact of the primary aetiology upon the clinical outcome of adults with childhood-onset GH deficiency. , 2007, European Journal of Endocrinology.

[27]  N. Mauras,et al.  Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. , 2005, The Journal of clinical endocrinology and metabolism.

[28]  P. Clayton,et al.  Consensus statement on the management of the GH-treated adolescent in the transition to adult care. , 2005, European journal of endocrinology.

[29]  W. Blum,et al.  Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. , 2004, The Journal of clinical endocrinology and metabolism.

[30]  D. Dunger,et al.  Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth. , 2004, The Journal of clinical endocrinology and metabolism.

[31]  G. Saggese,et al.  Indications and strategies for continuing GH treatment during transition from late adolescence to early adulthood in patients with GH deficiency: The impact on bone mass , 2004, Journal of endocrinological investigation.

[32]  R. Packer,et al.  Endocrine outcome in children with medulloblastoma treated with 18 Gy of craniospinal radiation therapy. , 2004, Neuro-oncology.

[33]  K. Attie,et al.  Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. , 2003, The Journal of clinical endocrinology and metabolism.

[34]  C. Quigley,et al.  Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. , 2003, The Journal of clinical endocrinology and metabolism.

[35]  C. Cowell,et al.  The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. , 2003, The Journal of clinical endocrinology and metabolism.

[36]  I. Bosaeus,et al.  Currently used growth‐promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents ‡ , 2001, Clinical endocrinology.

[37]  E. Arvat,et al.  Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test. , 2000, The Journal of clinical endocrinology and metabolism.

[38]  N. Skakkebaek,et al.  Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. , 2000, The Journal of clinical endocrinology and metabolism.

[39]  B. Bengtsson,et al.  Discontinuation of Growth Hormone (GH) Treatment: Metabolic Effects in GH-Deficient and GH-Sufficient Adolescent Patients Compared with Control Subjects* , 1999 .

[40]  J. Jørgensen,et al.  Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition , 1996, Clinical Endocrinology.

[41]  J. Kaufman,et al.  Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. , 1992, The Journal of clinical endocrinology and metabolism.